Navigation Links
United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
Date:7/26/2012

SILVER SPRING, Md., July 26, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2012.

"I am pleased with our second quarter results, which reflect the continued strength of our core business," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I am also pleased that our Board authorized an additional $100 million share repurchase program to return further value to our shareholders, which we announced at the end of June."Total revenues for the quarter ended June 30, 2012 were $225.6 million, up from $183.8 million for the quarter ended June 30, 2011. Net income for the quarter ended June 30, 2012 was $72.3 million or $1.37 per basic share, compared to $73.9 million or $1.27 per basic share for the same quarter in 2011. Gross margin from sales was $192.2 million for the quarter ended June 30, 2012, compared to $162.4 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended June 30, 2012 were $127.7 million, compared to $93.5 million for the same quarter in 2011.

Financial Results for the Three Months Ended June 30, 2012 Revenues

The table below summarizes the components of net revenues (dollars in thousands):Three Months EndedJune 30,PercentageChange20122011Cardiopulmonary products:Remodulin

$

110,398$

104,8945.2

%Tyvaso

81,21061,80931.4

%Adcirca

30,22416,84379.4

%Other

3,7452051,726.8

%Total net revenues

$

225,577$

183,75122.8

%Revenues for the quarter ended June 30, 2012 increased by $41.8 million, compared to the same quarter in 2011. The growth in product revenues reflects the increase in the number of patients being prescribed our products.  For the quarter ended June 30, 2012, other revenue includes the recognition of $2.0 million of deferred revenue as the result of the termination of a license agreement and the resulting termination of our obligation to perform future services.

 

________________________

(1)
See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.

 

Expenses

The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,Percentage Change20122011Project and non-project component:Cardiopulmonary

$

22,058$

24,490(9.9)

%Share-based compensation expense (benefit)

4,221(9,555)144.2

%Other

10,8209,30516.3

%Total research and development expense

$

37,099$

24,24053.0

Share-based compensation. The increase in share-based compensation of $13.8 million for the quarter ended June 30, 2012, compared to the same quarter in 2011, corresponded to the increase in the price of our common stock.

 

The table below summarizes selling, general and administrative expense by major categories (dollars in thousands):Three Months EndedJune 30,Percentage Change20122011Category:General and administrative

$

31,233$

24,26828.7

%Sales and marketing

17,13617,0720.4

%Share-based compensation expense (benefit)

4,889(17,484)128.0

%Total selling, general and administrative expense

$

53,258$

23,856123.2

General and administrative. The increase in general and administrative expenses for the quarter ended June 30, 2012, compared to the same quarter in 2011, corresponded principally to the recognition of a $6.8 million impairment loss equal to the net book value of a contract-based intangible asset due to the termination of the underlying contract.

Share-based compensation. The increase in share-based compensation of $22.4 million for the quarter ended June 30, 2012, compared to the same quarter in 2011, corresponded to the increase in the price of our common stock.

Income Taxes

The provision for income taxes was $31.0 million for the quarter ended June 30, 2012, compared to $35.7 million for the same quarter in 2011. The decrease in the provision for income taxes reflects lower pre-tax earnings for the quarter ended June 30, 2012, compared to the same quarter in 2011, and a decrease in the estimated annual effective tax rate to 32 percent as of June 30, 2012 from 34 percent as of June 30, 2011 reflecting an increase in the estimated annual deduction for domestic manufacturing.

2012 Revenue GuidanceWe reaffirm our 2012 full-year revenue guidance for our three commercial products (Remodulin®, Tyvaso® and Adcirca®), as we continue to expect related revenues to fall within a range of 5% above or below $875 million for 2012.Earnings Before Non-Cash ChargesEarnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) income taxes; (3) license fees; (4) depreciation and amortization; (5) impairment charges; and (6) share-based compensation (stock option and share tracking award expense).

A reconciliation of net income to earnings before non-cash charges is presented below (in thousands, except per share data):Three Months EndedJune 30,20122011Net income, as reported

$

72,316$

73,891Adjust for non-cash charges:Interest expense

3,8795,431Income tax expense

30,97435,723License fees

——Depreciation and amortization

6,2924,837Impairment charges

4,839(1)

609Share-based compensation expense (benefit)

9,447(27,037)Earnings before non-cash charges

$

127,747$

93,454Earnings before non-cash charges per share:Basic

$

2.42$

1.61Diluted

$

2.37$

1.49Weighted average number of common shares outstanding:Basic

52,74758,180Diluted

53,94262,756________________________

(1)
Consists of a $6.8 million impairment loss relating to a contract-based intangible asset, upon the termination of the underlying license agreement during the three months ending June 30, 2012, net of the $2.0 million of deferred revenue we recognized as a result of the terminated license agreement and the termination of our obligation to perform future services. Conference CallWe will host a half-hour teleconference on Thursday, July 26, 2012, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406 and using access code 96430669.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Non-GAAP Financial InformationThis press release contains a financial measure, earnings before non-cash charges, that does not comply with United States generally accepted accounting principles (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

We use earnings before non-cash charges to assist us in: (1) planning, including the preparation of our annual operating budget; (2) allocating resources in an effort to enhance the financial performance of our business; (3) evaluating the effectiveness of our operational strategies; and (4) assessing our capacity to fund capital expenditures and expand our business. We believe this non-GAAP financial measure enhances investors' understanding of our financial results by excluding certain expenses that we do not consider when evaluating and comparing the performance of our core operations and making operating decisions. In addition, we have historically reported earnings before non-cash charges to investors, and believe the inclusion of this non-GAAP financial measure provides investors with a consistent method of comparison to historical periods. However, there are limitations in the use of this non-GAAP financial measure in that it excludes certain operating expenses that are recurring in nature. In addition, our calculation of this non-GAAP financial measure may differ from the methodology used by other companies. The presentation of this non-GAAP financial measure should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.  A reconciliation of net income, the most directly comparable GAAP financial measure, to earnings before non-cash charges can be found in the table above under the heading, Earnings Before Non-Cash Charges.

Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations about future operating results, including our revenue guidance for 2012, and statements regarding future repurchases of our common stock. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of the date of this press release, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.

Adcirca is a registered trademark of Eli Lilly and Company.

 UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data)Three Months EndedJune 30,20122011(Unaudited)Revenues:Net product sales

$

221,832$

183,546Other

3,745205Total revenues

225,577183,751Operating expenses:Research and development

37,09924,240Selling, general and administrative

53,25823,856Cost of product sales

29,63321,162Total operating expenses

119,99069,258Operating income

105,587114,493Other (expense) income:Interest income

1,055839Interest expense

(3,879)(5,431)Equity loss in affiliate

(42)(30)Other, net

569(257)Total other (expense) income, net

(2,297)(4,879)Income before income taxes

103,290109,614Income tax expense

(30,974)(35,723)Net income

72,31673,891Net income per common share:Basic

$

1.37$

1.27Diluted

$

1.34$

1.18Weighted average number of common shares outstanding:Basic

52,74758,180Diluted

53,94262,756SELECTED CONSOLIDATED BALANCE SHEET DATAJune 30, 2012 (Unaudited, in thousands)Cash, cash equivalents and marketable securities (excluding restricted amounts of $5.4 million)

$

701,312Total assets

1,556,401Total liabilities and common stock subject to repurchase

546,802Total stockholders' equity

1,009,599 


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Approach to Growing Waste to Value Industry in United States
2. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
3. United States Rocket Academy Welcomes XCOR Aerospace to Texas
4. United Therapeutics Announces Additional $100 Million Share Repurchase Program
5. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
6. Strategic Analysis of the Collagen Peptide Market in the United States
7. Animal Husbandry Equipment Market in United States: Business Report 2011
8. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
9. Juventas Therapeutics Raises $22.2 Million Series B Financing
10. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
11. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... South Korea , Dec. 8, 2016 ... a $21 billion KRW (US $18.9M) Series A financing. ... Kolon Investment, G.N. Tech Venture and SNU Bio Angel. ... Eutilex to 30.5 billion KRW (US $27.7M) since its ... help Eutilex to bolster the development and commercialization of ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):